1. Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians.
- Author
-
Principe, Luigi, Lupia, Tommaso, Andriani, Lilia, Campanile, Floriana, Carcione, Davide, Corcione, Silvia, Rosa, Francesco Giuseppe De, Luzzati, Roberto, Stroffolini, Giacomo, Steyde, Marina, Decorti, Giuliana, and Bella, Stefano Di
- Subjects
CEFTAZIDIME ,BETA-lactamase inhibitors ,MEDICAL personnel ,ANTIBIOTICS ,CEFEPIME ,MEROPENEM ,AZTREONAM - Abstract
Bacterial resistance mechanisms are continuously and rapidly evolving. This is particularly true for Gram-negative bacteria. Over the last decade, the strategy to develop new β-lactam/β-lactamase inhibitors (BLs/BLIs) combinations has paid off and results from phase 3 and real-world studies are becoming available for several compounds. Cefiderocol warrants a separate discussion for its peculiar mechanism of action. Considering the complexity of summarizing and integrating the emerging literature data of clinical outcomes, microbiological mechanisms, and pharmacokinetic/pharmacodynamic properties of the new BL/BLI and cefiderocol, we aimed to provide an overview of data on the following compounds: aztreonam/avibactam, cefepime/enmetazobactam, cefepime/taniborbactam, cefepime/zidebactam, cefiderocol, ceftaroline/avibactam, ceftolozane/tazobactam, ceftazidime/avibactam, imipenem/relebactam, meropenem/nacubactam and meropenem/vaborbactam. Each compound is described in a dedicated section by experts in infectious diseases, microbiology, and pharmacology, with tables providing at-a-glance information. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF